OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.

Also called NCT07576257

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07576257
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07576257. Randomized; no masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)
Acronym
OPRA-HF Extens
Condition
Heart Failure
Intervention (Drug)
potassium binder
Lead sponsor
Sahlgrenska University Hospital (class: other)

Record details

Record id
cardio:ct-nct07576257
Content hash
d4ba20e3761375fabdefd5cb05f163cfca615e6c6bbacf0c82c3d4dc45c96655